Aegerion Pharmaceuticals Inc. (AEGR)

AEGR (NASDAQ:Drugs)
$62.13
neg -1.57
-2.46%
Today's Range: 62.04 - 64.36 | AEGR Avg Daily Volume: 698,400
Last Update: 06/19/13 - 4:00 PM EDT
Volume: 355,540
YTD Performance: 150.99%
Open: $64.36
Previous Close: $63.70
52 Week Range: $12.87 - $75.69
Oustanding Shares: 28,819,111
Market Cap: 1,835,777,371
6-Month Chart
TheStreet Ratings Grade for AEGR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 10 11
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.08 1.09 1.09 1.08
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -23.33
Price Earnings Comparisons:
AEGR Sector Avg. S&P 500
-23.33 0.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
64.18% 326.13% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.00 0.00 0.00
Net Income 0.00 4.11 0.00
EPS 0.00 -0.18 0.00
Earnings for AEGR:
EBITDA -0.06B
Revenue 0.00B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $-0.62 $-0.56 $-2.28 $0.64
Number of Analysts 7 6 8 7
High Estimate $-0.55 $-0.41 $-1.91 $3.16
Low Estimate $-0.71 $-0.69 $-2.61 $-0.49
Prior Year $-0.60 $-0.59 $-2.58 $-2.28
Growth Rate (Year over Year) -3.57% 5.37% 11.48% 127.90%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishAegerion Pharmaceuticals price target raised at J.P. Morgan

Jun 12, 2013 | 8:26 AM EDT

AEGR price target was raised to $88, J.P. Morgan said. Encouraging physician feedback and the recent approval recommendation for Lojuxta have improved the valuation outlook.

bullishAegerion Pharmaceuticals target raised at Jefferies

Dec 27, 2012 | 7:54 AM EST

Shares of AEGR now seen reaching $29, Jefferies said. Juxtapid approval. Buy rating.

The Next Big Thing In Biotech: FDA Decisions

By

Adam Feuerstein and Gregg Greenberg

 | Dec 14, 2012 | 5:30 AM EST

Adam Feuerstein, Sr. Columnist for TheStreet, says three big FDA drug approval decisions are the next big things to watch in biotech.

Columnist Conversation / Market Updates

Back to Divine
By

Doug Kass

 | Jun 20, 2013 | 7:10 AM EDT
Divine, Towards your point... In yesterdy's opener I made this observation: "Bill King's The King Report writes that Chi...

SHIBOR
By

Helene Meisler

 | Jun 20, 2013 | 6:47 AM EDT
Do not confuse me with a macro trader. Do not confuse me with anyone who knows anything about the credit markets either....
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.